In the human male, testosterone is the major circulating androgen. More than 95% of circulating testosterone is secreted by the testis with a production rate of 6–7 mg/day. The clinical effects of androgens are numerous, and testosterone deficiency is associated with a number of clinical abnormalities. Overt hypogonadism results in reductions in bone mineral density, alterations in body composition and effects on mood, aggressive behaviour, cognitive function, sexual function and several factors important for cardiovascular risk. Androgen replacement in this context is clearly beneficial, and numerous studies have demonstrated improvements in bone and muscle mass, reductions in body fat, and positive effects on quality of life following treatment. The benefits of therapy in men with milder degrees of hypogonadism, and elderly men with ‘physiological’ testosterone deficiency, are less clear-cut, and the appropriate biochemical cut-off below which replacement should be offered has not been clearly defined. Several options are available for androgen replacement in adult men. Oral testosterone, intramuscular injections, subcutaneous implants and transdermal therapy have all been used. Each mode of delivery has advantages and drawbacks and the choice between them will often depend on patient reference. Recent advances include the development of longer-acting intramuscular preparations, which offer more stable androgen levels with fairly infrequent injections, and testosterone gel which appears to provide transdermal replacement without a high incidence of skin reactions. This article will examine the evidence concerning the impact of male hypogonadism and the response to androgen therapy. The question of who to treat will be addressed with particular reference to mild hypogonadism and hypogonadism in the elderly. Finally, an overview of the different modes of replacement therapy will be presented.

1.
Coffey D: Androgen action and the sex accessory tissues; in E Knobil, J Neill (eds): Physiology of Reproduction. New York, Raven Press, 1988, pp 1081–1119.
2.
Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126(2):1165–1172.
3.
Katznelson L, Rosenthal DI, Rosol MS, Anderson EJ, Hayden DL, Schoenfeld DA, Klibanski A: Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. Am J Roentgenol 1998;170(2):423–427.
4.
Brodsky IG, Balagopal P, Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3469–3475.
5.
Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A: Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81(12):4358–4365.
6.
Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS: Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3654–3662.
7.
Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82(2):407–413.
8.
Bhasin S, Bross R, Storer T, Casaburi R: Androgens and muscle; in Nieschlag E, Behre H (eds): Testosterone: Action, Deficiency, Substitution. Berlin, Springer, 1998, pp 209–227.
9.
Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335(1):1–7, 52–53.
10.
Young NR, Baker HW, Liu G, Seeman E: Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrinol Metab 1993;77(4):1028–1032.
11.
Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C: Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82(6):1661–1667.
12.
Tenover JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75(4):1092–1098.
13.
Urban RJ, Bodenburg YH, Gilkison C, et al: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269(5 part 1):E820–E826.
14.
Morley JE, Perry HM 3rd, Kaiser FE, Kraenzle D, Jensen J, Houston K, Mattammal M, Perry HM Jr: Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41(2):149–152.
15.
Greendale GA, Edelstein S, Barrett Connor E: Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997;12(11):1833–1843.
16.
Drinka PJ, Olson J, Bauwens S, Voeks SK, Carlson I, Wilson M: Lack of association between free testosterone and bone density separate from age in elderly males. Calcif Tissue Int 1993;52(1):67–69.
17.
Meier DE, Orwoll ES, Keenan EJ, Fagerstrom RM: Marked decline in trabecular bone mineral content in healthy men with age: lack of association with sex steroid levels. J Am Geriatr Soc 1987;35(3):189–197.
18.
Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab 1993;76(2):288–290.
19.
Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69(3):523–527.
20.
Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr: Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106(3):354–361.
21.
Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley WF Jr: Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989;69(4):776–783.
22.
Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82(8):2386–2390.
23.
Anderson FH, Francis RM, Peaston RT, Wastell HJ: Androgen supplementation in eugonadal men with osteoporosis: effects of six months’ treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12(3):472–478.
24.
Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Piaseu N, Chailurkit L: Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf) 1998;49(6):803–809.
25.
Gooren LJ: Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 1987;16(6):463–473.
26.
Davidson JM, Camargo CA, Smith ER: Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979;48(6):955–958.
27.
Skakkebæk NE, Bancroft J, Davidson DW, Warner P: Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 1981;14(1):49–61.
28.
Anderson RA, Bancroft J, Wu FC: The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 1992;75(6):1503–1507.
29.
Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ: Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 1994;78(3):711–716. [Published erratum appears in J Clin Endocrinol Metab 1994;78(6):1520.]
30.
Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR, Galmarini M, Bhasin S: Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993;59(5):1118–1123.
31.
Scaramella TJ, Brown WA: Serum testosterone and aggressiveness in hockey players. Psychosom Med 1978;40(3):262–265.
32.
Christiansen K, Knussmann R: Androgen levels and components of aggressive behavior in men. Horm Behav 1987;21(2):170–180.
33.
Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ: Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994;79(2):561–567.
34.
Christiansen K: Behavioural correlates of testosterone; in Nieschlag E, Behre H (eds): Testosterone: Action, Deficiency, Substitution. Berlin, Springer, 1998, pp 107–142.
35.
Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS: Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3578–3583.
36.
Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ: A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992;13(4):297–304.
37.
Tchernof A, Labrie F, Belanger A, Prud’homme D, Bouchard C, Tremblay A, Nadeau A, Despres JP: Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 1997;133(2):235–244.
38.
Freedman DS, O’Brien TR, Flanders WD, DeStefano F, Barboriak JJ: Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler Thromb 1991;11(2):307–315.
39.
Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E: Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 1997;82(2):682–685.
40.
Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ: Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med 1992;116(12 part 1):967–973.
41.
Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M, Sadowski Z: Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996;121(1):35–43.
42.
Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A, Gundogan MA: Effects of gonadotropin and testosterone treatments on lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996;81(9):3372–3378.
43.
Yang XC, Jing TY, Resnick LM, Phillips GB: Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993;13(4):467–471.
44.
Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T: Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993;122(4):412–420.
45.
Anderson RA, Ludlam CA, Wu FC: Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995;74(2):693–697.
46.
Alexandersen P, Haarbo J, Christiansen C: The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996;125(1):1–13.
47.
English K, Birchall A, Pugh P, Channer K, Jones T: Low dose transdermal testosterone therapy improves myocardial ischaemia threshold and quality of life in patients with chronic stable angina [abstract]. Toronto, The Endocrine Society annual meeting, 2000, p 393.
48.
Jaffe MD: Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977;39(11):1217–1222.
49.
Wu SZ, Weng XZ: Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J Engl 1993;106(6):415–418.
50.
Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA: Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49(2):191–196.
51.
Hajjar RR, Kaiser FE, Morley JE: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82(11):3793–3796.
52.
Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL: Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670–2677.
53.
Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr: The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997;158(5):1775–1777.
54.
Clague JE, Wu FC, Horan MA: Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl 1999;22(4):261–265.
55.
Howell S, Radford J, Adams J, Smets E, Warburton R, Shalet S: Randomised placebo controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf), in press.
56.
Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol (Oxf) 1999;51(6):757–763.
57.
Behre HM, Nieschlag E: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992;75(5):1204–1210.
58.
Handelsman DJ, Conway AJ, Boylan LM: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;71(1):216–222.
59.
Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85(3):964–969.
60.
Swerdloff S, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Lonstreth J, Berman N: Long term pharmacokinetics of transdermal testosterone gel versus testosterone patch in hypogonadal men [abstract]. Toronto, The Endocrine Society annual meeting, 2000, p 567.
You do not currently have access to this content.